Cargando…

Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients

In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Petry, K-U, Menton, S, Menton, M, van Loenen-Frosch, F, de Carvalho Gomes, H, Holz, B, Schopp, B, Garbrecht-Buettner, S, Davies, P, Boehmer, G, van den Akker, E, Iftner, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377109/
https://www.ncbi.nlm.nih.gov/pubmed/12771924
http://dx.doi.org/10.1038/sj.bjc.6600918
_version_ 1782154779558936576
author Petry, K-U
Menton, S
Menton, M
van Loenen-Frosch, F
de Carvalho Gomes, H
Holz, B
Schopp, B
Garbrecht-Buettner, S
Davies, P
Boehmer, G
van den Akker, E
Iftner, T
author_facet Petry, K-U
Menton, S
Menton, M
van Loenen-Frosch, F
de Carvalho Gomes, H
Holz, B
Schopp, B
Garbrecht-Buettner, S
Davies, P
Boehmer, G
van den Akker, E
Iftner, T
author_sort Petry, K-U
collection PubMed
description In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade cervical intraepithelial neoplasia (CIN2+), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology for the detection of CIN2+ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0, 11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2+ was 97.8%, with a specificity, PPV and NPV, of 95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease, but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up management.
format Text
id pubmed-2377109
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23771092009-09-10 Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients Petry, K-U Menton, S Menton, M van Loenen-Frosch, F de Carvalho Gomes, H Holz, B Schopp, B Garbrecht-Buettner, S Davies, P Boehmer, G van den Akker, E Iftner, T Br J Cancer Molecular and Cellular Pathology In a prospective cohort study 8466 women attending routine cervical cancer screening were recruited. Colposcopy was performed on women with any degree of atypia on cytology and/or a positive high-risk human papillomavirus (HPV)-DNA test (HC2; Hybrid Capture 2(©)), and for a randomly selected sample of 3.4% women with negative findings on both. Quality control included reviews of cytology, histology, colposcopy images and retesting of samples with polymerase chain reaction. Test diagnostic performances were based on 7908 women who had complete baseline and follow-up results. Routine histology identified 86 women with high-grade cervical intraepithelial neoplasia (CIN2+), which was confirmed by review histology in only 46 cases. Sensitivity of routine cytology for the detection of CIN2+ was 43.5%, with a specificity, positive predictive value (PPV), negative predictive value (NPV) of 98.0, 11.4 and 99.7%, respectively. Sensitivity of the HC2 test for the detection of CIN2+ was 97.8%, with a specificity, PPV and NPV, of 95.3, 10.9 and 100%, respectively. No high-grade neoplasia was detected in the randomly selected control group. A negative HPV-test result, even in combination with a positive Papanicolaou (Pap) result, virtually excluded any risk of underlying high-grade disease, but this was not the case for a negative Pap result. These data show that HPV testing is of value for the detection or exclusion of prevalent CIN in a routine cervical cancer-screening setting and could be used for further risk classification of women for follow-up management. Nature Publishing Group 2003-05-19 2003-05-13 /pmc/articles/PMC2377109/ /pubmed/12771924 http://dx.doi.org/10.1038/sj.bjc.6600918 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Petry, K-U
Menton, S
Menton, M
van Loenen-Frosch, F
de Carvalho Gomes, H
Holz, B
Schopp, B
Garbrecht-Buettner, S
Davies, P
Boehmer, G
van den Akker, E
Iftner, T
Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title_full Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title_fullStr Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title_full_unstemmed Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title_short Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients
title_sort inclusion of hpv testing in routine cervical cancer screening for women above 29 years in germany: results for 8466 patients
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377109/
https://www.ncbi.nlm.nih.gov/pubmed/12771924
http://dx.doi.org/10.1038/sj.bjc.6600918
work_keys_str_mv AT petryku inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT mentons inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT mentonm inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT vanloenenfroschf inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT decarvalhogomesh inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT holzb inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT schoppb inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT garbrechtbuettners inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT daviesp inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT boehmerg inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT vandenakkere inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients
AT iftnert inclusionofhpvtestinginroutinecervicalcancerscreeningforwomenabove29yearsingermanyresultsfor8466patients